Conceptio
›
Archive
›
NCBI PubMed Central
NCBI PubMed Central
open access
AdvanTIG-206: a phase II, randomized study of ociperlimab plus tislelizumab and BAT1706 (bevacizumab biosimilar) versus tislelizumab and BAT1706 in first-line hepatocellular carcinoma.
Ren Z et al.
NCBI PubMed Central · Papers · License: Open Access
Open Source ↗
Direct PDF ↓
information security management
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗
Related documents
Force-Induced Control of Circularly Polarized Luminescence With Rotaxane Architecture.
#1054380
Dental school caries and periodontitis risk analysis skillset: survey of carryover to practice.
#1054381
Maternal and child health challenges during and after flooding: a qualitative study in Makassar, Indonesia.
#1054382
Genetic diversity of Camelina sativa: implications for sustainable crop improvement through Genotyping-by-Sequencing (GBS).
#1054383
'Poverty is the biggest barrier': stakeholder perspectives on social determinants of malaria in Wakiso District, Uganda.
#1054384
Record
· ID 146145
Retrieved via
Conceptio
— every document is proof-bundled with source, license, and retrieval metadata.